Intero Biosystems has built GastroScreen—the first and only iPSC-derived mini human intestine that recapitulates the major cell types and 3-D spatial organization of the gut.
What is the problem?
90% of new drugs fail clinical trials, wasting years of work and billions of dollars, leaving patients waiting. Roughly 75% of development costs are lost to failed candidates.
What is their solution?
Intero Biosystems has built GastroScreen—the first and only iPSC-derived mini human intestine that recapitulates the major cell types and 3-D spatial organization of the gut. Unlike other in-vitro models, GastroScreen includes a functional epithelium plus supporting tissues: smooth muscle that shows spontaneous, rhythmic peristalsis; perfusable microvessels; neurons that respond to stimuli; and the ability to add immune cells—creating a true “mini-gut in a dish.” Teams can use GastroScreen for preclinical assays, disease modeling, toxicity/safety testing, and functional studies of intestinal processes such as motility, immunology applications, and barrier function.
